SAN CARLOS, Calif., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that Timothy Morris, CFO, will present at the 2018 Cantor Global Healthcare Conference in New York, NY on Tuesday, October 2, 2018 at 2:15 p.m. ET in New York, NY.
A live audio webcast of the presentation will be available by visiting the Investors section of Iovance Biotherapeutics' website at http://ir.iovance.com. A replay of the webcast will be archived on Iovance Biotherapeutics’ website for 30 days following the presentation.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocyte (TIL) technology being investigated for the treatment of patients with metastatic melanoma, recurrent and/or metastatic squamous cell carcinoma of the head and neck, recurrent, metastatic or persistent cervical cancer, and locally advanced or metastatic non-small cell lung cancer. For more information, please visit http://www.iovance.com.
Investor Relations Contact:
Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
sarah@sternir.com
Media Contact:
John Capodanno
FTI Consulting
212-850-5705
john.capodanno@fticonsulting.com
Iovance Biotherapeutics, Inc.
